With Cipla’s continuous efforts in ensuring treatments to detect and challenge this COVID-19 pandemic, the new COVID-19 RT-PCR test kit ‘ViraGen’ by Cipla has been launched and is now available in the market. The drug major partnered with Ubio Biotechnology Systems for the development of this New ViraGen test kit. As per Cipla’s regulatory filing, this launch of the ViraGen COVID-19 test will aid in addressing the ongoing testing and diagnosis issues in COVID-19 due to capacity while moving forward with the company’s expansion in the diagnostic field.
This New COVID-19 RT-PCR test will be very fruitful to boost up the COVID-19 diagnosis. ViraGen Cipla test kit has concluded the lagging demand of diagnostic kit and hence the management of COVID-19. ViraGen COVID-19 test kit is Cipla’s third effort towards COVID-19 testing.
ViraGen COVID-19 test is Cipla’s latest offering towards COVID-19 management and care. ViraGen Cipla test kit has received approval from the Indian Council of Medical Research (ICMR) as a diagnostic kit for COVID-19. ViraGen Cipla test kit is a real-time detection kit. It is based upon the multiplex Polymerase Chain Reaction (PCR) technology.
ViraGen assists in the diagnosis and detection of the SARS-CoV-2 N gene and the ORF lab gene. It provides specificity of 98.8% and a sensitivity of 98.6% when compared with the ICMR standard tests. ViraGen Cipla test kit performs qualitative detection. ViraGen COVID-19 test kit detects the nucleic acid from SARS-CoV-2, both in the lower and the upper respiratory specimens from individuals who have symptoms of COVID-19.
With the COVID-19 infection being widespread, there is always a need for diagnostic kits which can detect the virus at the initial stages and help in controlling further expansion. There has been antigen testing and RT-PCR testing being extensively used to track down and break the chain of coronavirus infection. Cipla has already partnered for antigen and antibody detection kits. This New COVID-19 RT-PCR test kit is now easily accessible from the market. The ViraGen COVID test kit is one step forward towards this motive by Cipla. Cipla has also taken various other efforts towards the ongoing COVID-19 pandemic in the past.
At present, the real-time PCR test is the uttermost reliable, accurate and preferred method for the detection of COVID-19 in symptoms. ViraGen COVID-19 test being the real-time detection kit provides the highest accuracy and diagnosis if there is the existence of coronavirus in your system. The test involves sampling on a nasal swab or a throat swab that is sent to a laboratory to be analysed for further diagnosis. The RT-PCR test continues to be the ”gold standard” for diagnosing COVID-19.
India, being one of the most populated countries, turned into a COVID-19 warplace. The need for diagnosis of COVID-19 before one individual infects another individual is crucial. The New ViraGen test kit was the need of the hour. This New COVID-19 RT-PCR test kit will help manage the volume. A densely populated country like India will benefit from the ViraGen Cipla test kit. Cipla has used its market distributors to make sure that ViraGen is available in the market from May 25, 2021.
In case one shows symptoms of COVID-19 infection like high fever, dry cough, loss of smell or taste, sore throat or breathing issue, it would be smart to choose the New ViraGen test kit to have accurate results. Even if one may have been in contact with any individual who has tested positive, they should undergo COVID-19 testing.
In case you are diagnosed positive of COVID-19, isolate yourself to protect the ones you love and stop the infection chain. Keep a thermometer and oximeter handy and maintain track of your temperature and oxygen levels. Contact your healthcare provider immediately and take the medications as per their suggestion. Also, do not stop taking the precautionary measures of covering your face and mouth and regular sanitisation of hands to control the spread of the virus.
Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.
Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.
Recently there has been another medical breakthrough in the fight against COVID-19. The Indian Council of Medical Research (ICMR) has approved a home Rapid Antigen testing (RAT) kit for COVID-19. According to the ICMR, the COVID-19 home test kit manufactured by Mylab Discovery Solutions Ltd, Pune, has been validated and approved. The ICMR has clearly stated that since the COVID-19 home test is a nasal swab test it should be conducted as per the instructions given by the manufacturer in the user manual.
The COVID-19 RAT test enables people to collect their nasal sample and test if they are COVID-19 positive. With the pandemic spreading like wildfire in many states of India, there is immense pressure on diagnostic labs conducting RT-PCR tests. Moreover, the RT-PCR test takes two to three days to give results which delay the start of treatment for positive patients. The ICMR has now approved the COVID-19 home test kit as it gives quick results in fifteen minutes. The guidelines that need to be followed while conducting the COVID-19 RAT test are given below.
The company manufacturing the COVID-19 home test kits promises to make millions of kits for India and that too at an inexpensive price. India has a huge population and regular testing through RT-PCR is not only impossible but also expensive. As a result, many avoid getting tested despite having symptoms. The self-testing kit being cheaper is accessible to a huge portion of the population who earlier refrained from getting tested.
The person using the COVID-19 home test kit must download MyLab’s AI-powered mobile app to get their reports as soon as possible. The home testing mobile app is available in the Google Play store and Apple store and must be downloaded by all users. The mobile app submits the result to ICMR immediately so that patients can get their reports and start treatment if found COVID-19 positive.
The mobile app is a comprehensive guide of the testing procedure and will provide a positive or negative test result to the patient. All users ‘MUST’ click a picture of the test strip after completing the test procedure with the same mobile phone which has been used for downloading the mobile app and user registration.
The home RAT test for COVID-19 is a significant step in our fight against COVID-19. Although less sensitive, it gives patients a sense of direction to start isolation and treatment as soon as found positive. Rapid antigen tests are also cheaper compared to RT-PCR and reduce the excessive pressure and the dependence on RT-PCR tests. But you should consciously follow the instructions given by both ICMR and the home testing kit company before conducting the test at home.
Disclaimer: The information provided here is for educational/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.
Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.
